MD Anderson, Invectys, CTMC announce strategic collaboration for CAR T-cell therapy development

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The University of Texas MD Anderson Cancer Center, Invectys Inc., and the Cell Therapy Manufacturing Center, a joint venture between MD Anderson and National Resilience Inc., announced a strategic collaboration to jointly develop a process for human leukocyte antigen-G targeted CAR T-cell therapy for solid tumors.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Wugen Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, announced it will initiate a phase II study in the first quarter of 2025 for the company’s potential first-in-class, investigational, anti-CD7 CAR T-cell therapy, WU-CART-007, in patients with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.
The University of Texas MD Anderson Cancer Center hosted its ninth annual Boot Walk to End Cancer fundraising event on Nov. 2, in the Texas Medical Center. This year, the Boot Walk’s 7,000+ in-person participants and 1,200+ virtual participants from Houston and around the world joined together to raise $1.4 million to support the institution’s mission to end cancer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login